1-2 of 2
Yusri A Elsayed, MD, PhD
Close
Sort by
Journal Articles

Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients

Suzette Girgis, PhD BPharm, MS, Shun Xin Wang Lin, PhD, Kodandaram Pillarisetti, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Shoba Shetty, PhD, Tara Stephenson, PhD, Brandi W. Hilder, PhD, Brett Hanna, Jennifer Smit, Homer Adams III, PhD, Yu-Nien (Tom) Sun, PhD, Jeffrey R. Infante, MD, Yusri A Elsayed, MD PhD, Amarnath Sharma, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-140565
Published: 2020
Journal Articles

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Bertrand Coiffier, MD, Weimin Li, Erin D Henitz, BS, J. D. Karkera, PhD, Reyna Favis, PhD, Dana Gaffney, MS, Alice Shapiro, MS, Panteli Theocharous, BSc (hons), MSc, PhD, Yusri A Elsayed, MD, PhD, Helgi van de Velde, MD, PhD, Evgenii A Osmanov, MD, PhD, Xiaonan Hong, MD, Adriana Scheliga, MD, Fritz C. Offner, MD, PhD, Simon Rule, Adriana C Teixeira, MD, Jan Walewski, MD, PhD, Sven de Vos, MD, PhD, Michael Crump, MD, FRCPC, Ofer Shpilberg, MD, MPH, Pier Luigi Zinzani, MD, PhD, Andrew Z Cakana, MD, FRCPath, Dixie-Lee Esseltine, MD, FRCPC, George Mulligan, PhD, Deborah S Ricci, PhD
Journal: Blood
Blood (2011) 118 (21): 265.
https://doi.org/10.1182/blood.V118.21.265.265
Published: 2011